Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk. - Wikidata - wikimedia - TriplyDB

Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.

Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.

http://www.wikidata.org/entity/Q38090988

about

Acute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies)Real-time, aptamer-based tracking of circulating therapeutic agents in living animals.Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shock How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock.Aminoglycosides use in patients over 75 years old.Aminoglycoside-induced nephrotoxicity--a focus on monitoring: a review of literature.Treatment option for sepsis in children in the era of antibiotic resistance.Acute kidney injury induced by antimicrobial agents in the elderly: awareness and mitigation strategies.Short-Course Adjunctive Gentamicin as Empirical Therapy in Patients With Severe Sepsis and Septic Shock: A Prospective Observational Cohort Study.Dose Timing of Aminoglycosides in Hemodialysis Patients: A Pharmacology View.Does the availability of therapeutic drug monitoring, computerised dose recommendation and prescribing decision support services promote compliance with national gentamicin prescribing guidelines?Should the aminoglycoside β-lactam combination be abandoned in all severely ill patients with presumed Gram-negative infection?Update on ventilator-associated pneumonia.Susceptibility of Imipenem-Susceptible but Meropenem-Resistant blaIMP-6-Carrying Enterobacteriaceae to Various Antibacterials, Including the Siderophore Cephalosporin Cefiderocol.Drug-associated acute kidney injury: who's at risk?

P2860

Q26745670-09D527AD-4112-4B7E-843D-6476A43B363F Q33570021-DC1151DD-06F0-4D0A-8533-26581DD35147 Q34597640-CC278A5E-871C-4878-8B14-760B82502A0E Q34894900-DFBA2C05-4EB7-4CD0-B1EA-E510E061B942 Q36089167-61E9096E-2412-42D0-9CCE-8CCC26EBB393 Q37389435-75FF947B-D254-44F5-A912-B16FDD733317 Q38192961-F31DDBC3-39F4-4809-834B-BE501EF43B17 Q38239999-05A753D1-22EF-4508-83A7-84FB1CC104D3 Q38246118-B144144A-A4B1-474B-AF34-39CBFD7BE6F2 Q38285837-1AF77834-4184-4EA6-BA18-D1B7B5700A9C Q38432516-A6E26D1C-04A3-4313-B5A8-4C7E7535A41D Q38693212-162B2884-BB25-453A-8507-D02B5428A4A2 Q41676743-B501F90B-F64B-4F93-B130-021F0202DF4F Q41987148-2BB4D71B-F645-4EF1-9366-068BAF3A73D4 Q47129727-346A70D1-4CFE-4DCF-A7FD-1788DBB35FA4 Q53742712-2E33B3AF-2E85-46D9-BF41-8A3345F186D1 Q53946600-D0AD7486-28C7-4AC9-8037-4812E208141F

P2860

Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.

http://www.wikidata.org/entity/Q38090988

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Aminoglycosides in septic shoc ...... ven to their nephrotoxic risk.

@en

type

label

Aminoglycosides in septic shoc ...... ven to their nephrotoxic risk.

@en

prefLabel

Aminoglycosides in septic shoc ...... ven to their nephrotoxic risk.

@en

P1433

Q38090988-8EA0D110-AF3F-45EE-98C9-3A66D17B904F

P1476

Q38090988-26CCF4D1-B035-4822-BB42-5C0FA328D185

P2093

Q38090988-068D6120-3DD0-4BA7-B6E5-DA764CED2322

Q38090988-0C6E62CE-8946-4767-B3AA-DFD4314C0CEC

Q38090988-23469D9F-B844-4482-AB29-24FA449F1B5A

Q38090988-281F636E-D5EF-483E-A4E5-2C0AC25FE6BA

Q38090988-4F01F646-8D23-4B5E-A3A7-9147636D5011

Q38090988-5F418DD6-2F33-4879-81B2-3A82407A7155

Q38090988-9847CEC8-F146-4AAA-A818-29BAA2858232

Q38090988-ADDBE6C5-B570-4033-B6FE-4B1ECFD6C484

Q38090988-BA57A42A-FA07-49B9-ABFE-D3F6C7822145

Q38090988-BF2F4EC8-2CDD-480A-9350-E559214F7C50

P2860

Q38090988-00F4F1A2-BE4B-476D-AFFC-A5FBAD24BAD6

Q38090988-0125A2F6-0BA4-436C-B35F-D5A0142AFEFF

Q38090988-018C0EB7-0757-4703-A463-DD6BD61D475C

Q38090988-0814A85A-5C5C-4F8B-9BBD-56FDCC7040EA

Q38090988-0998BA59-3E8D-4CEF-9772-E15984FD10EE

Q38090988-1135B1BC-854B-4F0D-AC0B-C9EB7E3BFB84

Q38090988-117AD942-AD95-43BC-A43A-9FCBCA6ACCB4

Q38090988-14751834-EB6F-4FAF-9931-0FD81EE3A25E

Q38090988-17F63DDE-7D3D-4FF9-8F3B-41DDD45C5210

Q38090988-1F381B20-0079-4DF9-9AFD-160EB3EEE67B

P2888

Q38090988-C72FD0FC-7B67-41E7-B7B3-F10E7AA8C1D4

P304

Q38090988-0CE61AE2-A990-4CFC-9A1B-B47FC70D1902

P31

Q38090988-1AEE4F0E-DFDB-4E14-92D9-AFF75D461B9D

P356

Q38090988-F52CCD56-4B69-4AD1-8A70-168713D14E17

P433

Q38090988-6B5F2CEC-6F6C-42CE-97B7-BE54061BB457

P478

Q38090988-A9A9C9E2-8623-4F3B-9A36-C15E15154AF6

P577

Q38090988-DF905656-CA16-4F87-85E0-5045323262CA

P6179

Q38090988-1C065BF7-85C6-4E4B-B417-4A2E85CE04B1

P698

Q38090988-51C5E31B-A264-45B9-A0CC-154E586F1B0E

P921

Q38090988-E952B327-AB36-4A52-92B2-4DAB869A5A61

P356

S40264-013-0031-0

P1433

P1476

Aminoglycosides in septic shoc ...... ven to their nephrotoxic risk.

@en

P2093

Alexandre Boyer

http://www.w3.org/2001/XMLSchema#string

Anne-Marie Rogues

http://www.w3.org/2001/XMLSchema#string

Benjamin Clouzeau

http://www.w3.org/2001/XMLSchema#string

Bui Hoang-Nam

http://www.w3.org/2001/XMLSchema#string

Didier Gruson

http://www.w3.org/2001/XMLSchema#string

Frédéric Vargas

http://www.w3.org/2001/XMLSchema#string

Hilbert Gilles

http://www.w3.org/2001/XMLSchema#string

Mathieu Molimard

http://www.w3.org/2001/XMLSchema#string

Nicholas Moore

http://www.w3.org/2001/XMLSchema#string

Stéphane Bouchet

http://www.w3.org/2001/XMLSchema#string

P2860

Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group

A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials

Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia.

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis.

Critical care of the bariatric patient.

Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials.

The economic impact of once-daily versus conventional administration of gentamicin and tobramycin.

Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring.

Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring.

P2888

s40264-013-0031-0

P304

217-230

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40264-013-0031-0

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1010536097

http://www.w3.org/2001/XMLSchema#string

P698

23508544

http://www.w3.org/2001/XMLSchema#string

P921